<DOC>
	<DOCNO>NCT01463384</DOCNO>
	<brief_summary>Cognitively normal individual , patient Mild Cognitive Impairment ( MCI ) Alzheimer 's Disease ( AD ) undergo clinical screening , neuropsychological test , blood urine analysis , quantitative magnetic resonance imaging ( MRI ) proton ( 1H ) carbon 13 ( 13C ) magnetic resonance spectroscopy ( MRS ) . Each individual receive minocycline oral administration 4 week initially , MRI , MRS neuropsychological result record . If adverse side effect occur , subject continue minocycline administration additional 5 month .</brief_summary>
	<brief_title>Minocycline Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>In course on-going trial novel MRI procedure Neurological Diagnosis , investigator establish non-invasive BIOMARKERS ( Note : Biomarkers objective Laboratory test use , replace Clinical diagnostic criterion disease , case age-related dementia Alzheimer type pre-clinical form include Mild Cognitive Impairment - MCI ) significantly assist Diagnosis Alzheimer 's Disease . MRS , rather like blood test apply screen exclusion medical disorder , provide pattern brain chemical many diagnosis become available ( see : Magnetic Resonance Spectroscopy Neurological Diagnosis : E.R Danielsen B.D . Ross , Marcel Dekker New York , 1999 ) . Diagnosis Alzheimer 's Disease hitherto exclusively clinical diagnosis , make basis non-specific test treat physician/neurologist . Furthermore , treatment limit efficacy pressure conclusive diagnosis objective characterization disease progression ( well , regression ) priority . This conservative approach Alzheimer 's Disease change 2010 Report National Institutes Aging . First : The failure treatment ascribed introduction patient advanced disease ( `` dementia '' ) . Second : A preliminary form AD , know pre-clinical Mild Cognitive Impairment , recognize , distinct , generally early disease course . Third : A new set diagnostic criterion , include objective 'biomarkers ' , cerebrospinal fluid , genetic imaging analyzes , accept Expert Panel . Finally , Clinical trial exist new drug Alzheimer 's Disease expect yield well result initiate early - pre-clinical phase - outcome evaluate earlier change approve panel biomarkers .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Cognitively normal elderly subject age 5590 patient age 55 90 year mild cognitive impairment ( MCI ) clinically define Alzheimer 's disease . Any person medical device cardiac pacemakers/defibrillators neuroimplants contraindication MRI/MRS exam . Since effect MRI unknown fetus unborn child , person may pregnant exclude study . History know allergy intolerance minocycline tetracycline Impaired renal function ( plasma Creatinine ) blood urea nitrogen ( BUN ) level exceed twice normal upper limit result high serum level tetracycline , azotemia , hyperphosphatemia acidosis .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Magnetic Resonance Spectroscopy</keyword>
	<keyword>Neuroinflammation</keyword>
	<keyword>Mild Cognitive Impairment</keyword>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Minocycline</keyword>
</DOC>